ALPS Advisors’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$778K Sell
4,042
-165
-4% -$17.8K ﹤0.01% 755
2026
Q2
$295K Buy
+4,207
New +$218K ﹤0.01% 1087
2023
Q1
– Sell
-2,406
Closed -$432K – 1093
2022
Q4
$432K Sell
2,406
-10
-0.4% -$1.64K ﹤0.01% 634
2022
Q3
$286K Buy
2,416
+81
+3% +$12.3K ﹤0.01% 879
2022
Q2
$334K Sell
2,335
-24
-1% -$3.43K ﹤0.01% 719
2022
Q1
$406K Buy
2,359
+1,492
+172% +$251K ﹤0.01% 472
2021
Q4
$220K Buy
867
+18
+2% +$5.26K ﹤0.01% 869
2021
Q3
$327K Buy
+849
New +$313K ﹤0.01% 838

Other funds holding MRNA

ALPS Advisors's MRNA Position: Q3 2026 in Review

ALPS Advisors reduced its Moderna (MRNA) stake by 3.9% in Q3 2026, selling an estimated $17.8K and leaving 4,042 shares worth $778K. The position accounts for ﹤0.01% of the portfolio, ranked #755.

ALPS Advisors first reported a position in MRNA in Q3 2021 and has held it in 8 quarters since. 1,044 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • ALPS Advisors held 4,042 shares of Moderna worth $778K as of Q3 2026.
  • ALPS Advisors sold 165 Moderna shares in Q3 2026, an estimated $17.8K.
  • Moderna made up ﹤0.01% of ALPS Advisors's portfolio in Q3 2026, its #755 holding.
  • ALPS Advisors first reported a position in Moderna in Q3 2021 and has held it in 8 quarters since.
  • 1,044 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on ALPS Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.